Clinical Rationale For Newer Anti-Seizure Medications
- Approximately 20% to 30% of children with epilepsy develop Drug-Resistant Epilepsy (DRE), defined as failure of two appropriately chosen and tolerated anti-seizure medication (ASM) schedules.
- Developmental and Epileptic Encephalopathies (DEEs) such as Dravet syndrome, Lennox-Gastaut syndrome (LGS), and Tuberous Sclerosis Complex (TSC) have poor response rates to traditional sodium channel blockers and GABAergic agents.
- Newer ASMs offer novel non-overlapping mechanisms of action, superior behavioral tolerability, and syndrome-specific efficacy.
1. Brivaracetam (BRV)
- Mechanism: High-affinity, selective ligand for Synaptic Vesicle Protein 2A (SV2A), exhibiting a 15- to 30-fold higher binding affinity than levetiracetam.
- Rapid brain penetration and high selectivity translate to significantly fewer neurobehavioral adverse events (such as aggression, irritability, and hyperactivity).
- Indications: Monotherapy or adjunctive therapy for focal-onset seizures in children aged $\ge 1$ month (FDA) and $\ge 2$ years (IAP).
- Dosing: 1 to 4 mg/kg/day orally or IV divided twice daily.
- Useful when transitioning patients experiencing levetiracetam-induced behavioral toxicity; a direct 10:1 switch (e.g., 1000 mg levetiracetam switched directly to 100 mg brivaracetam) can be made overnight without loss of seizure control.
2. Cenobamate (Xcopri)
- Mechanism: Novel dual mechanism combining inhibition of persistent sodium currents ($I_{\text{NaP}}$) and positive allosteric modulation of $GABA_A$ receptors at non-benzodiazepine binding sites.
- Efficacy in DRE: Demonstrates unprecedented seizure freedom rates (20% to 30%) and $\ge 50\%$ responder rates exceeding 70% in refractory focal epilepsy trials.
- Real-world pediatric off-label data in adolescents show high responder rates in focal DRE and LGS.
- Dosing And Titration: Must follow a strict, slow biweekly titration schedule to prevent Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome).
- Caution: Can cause dose-dependent somnolence, fatigue, and shortening of the QTc interval on ECG. Can exacerbate seizures in Dravet syndrome due to sodium channel inhibition.
3. Fenfluramine (Fintepla)
- Mechanism: Dual serotonergic mechanism acting as a 5-$HT_{1D}$, 5-$HT_{2A}$, and 5-$HT_{2C}$ receptor agonist, and a positive allosteric modulator of sigma-1 receptors.
- Indications:
- Dravet syndrome in patients aged $\ge 2$ years.
- Lennox-Gastaut syndrome (LGS) in patients aged $\ge 2$ years.
- Efficacy: Profound reduction in convulsive seizure frequency (up to 70% to 80% reduction in convulsive seizures in Dravet, and significant reduction in drop seizures in LGS).
- Dosing:
- Without stiripentol: $0.2\text{ mg/kg/day}$ titrated to a maximum of $0.7\text{ mg/kg/day}$ (max 26 mg/day).
- With concomitant stiripentol: Maximum dose is reduced to $0.4\text{ mg/kg/day}$ (max 17 mg/day).
- Safety Monitoring: Historically associated with cardiac valvulopathy and pulmonary arterial hypertension at high anorectic doses. Baseline and every 6-month Doppler echocardiography is mandatory.
- Common adverse events: Decreased appetite, weight loss, diarrhea, and fatigue.
4. Cannabidiol (Epidiolex)
- Mechanism: Highly purified, plant-derived oral solution of non-psychoactive phytocannabinoid.
- Acts via antagonism of G-protein-coupled receptor 55 (GPR55), desensitization of TRPV1 channels, and modulation of intracellular calcium.
- Indications: Adjunctive therapy for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex in patients aged $\ge 1$ year.
- Dosing: Starting dose is $5\text{ mg/kg/day}$ divided twice daily, titrated weekly to $10\text{–}20\text{ mg/kg/day}$ (up to $25\text{ mg/kg/day}$ in TSC).
- Drug Interactions And Monitoring:
- Potent inhibitor of CYP2C19: Causes a 3-fold elevation in $N$-desmethylclobazam (active metabolite of clobazam), producing profound somnolence requiring clobazam dose reduction.
- Concomitant use with sodium valproate significantly increases the risk of transaminase elevation; monitor baseline and periodic ALT, AST, and total bilirubin.
5. Everolimus (Afinitor) in Tuberous Sclerosis Complex (TSC)
- Pathophysiological Target: Inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin) lead to constitutive hyperactivation of the Mammalian Target of Rapamycin Complex 1 (mTORC1) pathway, driving cortical tuber formation, dysplastic neurons, and hyperexcitable neural circuits.
- Mechanism: Orally active mTORC1 inhibitor that targets the underlying biochemical driver of epilepsy in TSC.
- Indications (EXIST-3 Trial): Adjunctive treatment of refractory focal-onset seizures associated with Tuberous Sclerosis Complex in patients aged $\ge 2$ years.
- Dosing: Titrated to maintain therapeutic blood trough levels of 5 to 15 ng/mL.
- Co-Benefits: Concurrently reduces the size of Subependymal Giant Cell Astrocytomas (SEGA) and renal angiomyolipomas.
- Adverse effects: Aphthous stomatitis (most common), opportunistic infections, hyperlipidemia, hypertriglyceridemia, and non-infectious pneumonitis.
Comparative Summary Of Newer ASMs
| Drug | Primary Target / Mechanism | Approved Syndromes / Age | Key Monitoring / Adverse Effects |
|---|---|---|---|
| Brivaracetam | Selective SV2A ligand | Focal seizures ($\ge 1\text{ month}$) | Somnolence, dizziness; superior behavioral profile to levetiracetam |
| Cenobamate | Dual: $I_{\text{NaP}}$ blocker + $GABA_A$ PAM | Refractory focal epilepsy | Slow titration required (DRESS risk); QTc shortening, somnolence |
| Fenfluramine | 5-$HT_2$ agonist + sigma-1 modulator | Dravet syndrome, LGS ($\ge 2\text{ yrs}$) | Mandatory echocardiography (valvulopathy/PAH); decreased appetite |
| Cannabidiol | GPR55 antagonist, TRPV1 modulator | Dravet, LGS, TSC ($\ge 1\text{ year}$) | Liver transaminases (especially with valproate); clobazam sedation |
| Everolimus | mTORC1 pathway inhibitor | Refractory focal epilepsy in TSC ($\ge 2\text{ yrs}$) | Trough levels (5–15 ng/mL); stomatitis, hyperlipidemia, infections |